Oral dexamethasone pulse therapy versus daily prednisolone in sub-acute onset myositis, a randomised clinical trial
Introduction
Dermatomyositis, polymyositis, and non-specific myositis are immune-mediated myopathies and have an estimated prevalence of one per 100,000 population. These disorders are characterised by sub-acute-onset, progressive muscle weakness and inflammation in the skeletal muscle. They often cause severe chronic disability, and may be complicated by life-threatening impairment of swallowing and lung function [1]. First-line treatment consists of a 4 week course of high-dose daily oral prednisone (1–1.5 mg/kg/day), followed by slow tapering to prevent relapses, although this has never been investigated in a placebo-controlled trial [2]. This long-term treatment with corticosteroids is often complicated by debilitating side effects such as diabetes mellitus, hypertension, mood changes, weight gain, gastric symptoms and osteoporosis. To perform a placebo-controlled trial would nowadays be considered unethical. Other immunosuppressive drugs can be used as add-on medication but are usually not as effective, stressing the need for alternative first-line treatment strategies with fewer side effects [3]. Oral dexamethasone is seven times more potent than prednisone and pulsed schemes have been successfully used in other autoimmune diseases as an alternative to prednisone [4], [5], [6], [7], [8], [9], [10], [11]. Dexamethasone was well tolerated with fewer side effects than prednisone. Previously, we performed a small open-label study with pulsed dexamethasone as initial first-line treatment on patients with idiopathic inflammatory myopathies, sporadic inclusion body myositis (sIBM) excluded, who showed a quick improvement without severe side effects [12]. Based on these promising results we initiated a clinical trial to investigate whether high-dose pulsed oral dexamethasone is more effective and safer than daily high-dose prednisolone as first-line treatment in newly diagnosed adult patients with myositis.
Section snippets
Methods
We performed a multicentre, double-blind, randomised trial with 18 months follow-up. Patients’ consent was obtained according to the Declaration of Helsinki. The study protocol was approved by the medical ethics committees of all participating hospitals. Written informed consent was obtained from all patients before study entry. The Data Safety Monitoring Board comprised an independent neurologist, a biostatistician and a clinical epidemiologist who monitored possibly unfavourable events and the
Characteristics of the patients
Of the 162 patients screened between July 2001 and February 2007, 62 were randomised (Fig. 1): 32 in the prednisolone group and 30 in the dexamethasone group. None of the patients met the criteria for polymyositis [15]. All patients diagnosed with dermatomyositis had one or more characteristic skin abnormalities. Baseline characteristics of the study population are described in Table 1. The two groups were comparable regarding their demographic and clinical features.
A total of 38 (61%) patients
Discussion
This is the first long-term RCT comparing first-line treatment of idiopathic inflammatory myopathies, sporadic inclusion body myositis excluded. No statistically significant difference in the primary composite outcome scores of dexamethasone-treated or prednisolone-treated patients was found. However, a more favourable side-effect profile was observed in dexamethasone-treated patients, probably by the intermittent administration. This was most conspicuous with regard to the occurrence of
Funding
This work was supported by a Grant from the Prinses Beatrix Fonds (The Hague), Grant No. MAR02-0107.
Acknowledgment
We thank: all patients for participating in the study; Data and Safety Monitoring Board: P.A. van Doorn (Erasmus Medical Center, Rotterdam), A. Algra (University Medical Center, Utrecht), I. van der Tweel (University Medical Center, Utrecht); Steering Committee: J.W.J. Bijlsma (University Medical Center, Utrecht), J.H.J. Wokke (University Medical Center, Utrecht), B.G.M. van Engelen (University Medical Center St. Radboud, Nijmegen), F.H.J. van den Hoogen (University Medical Center St. Radboud,
References (36)
Therapeutic targets in patients with inflammatory myopathies: present approaches and a look to the future
Neuromuscul Disord
(2006)- et al.
Polymyositis and dermatomyositis
Lancet
(2003) - et al.
Et al. 119th ENMC international workshop: trial design in adult idiopathic inflammatory myopathies, with the exception of inclusion body myositis. 10–12 October 2003, Naarden, The Netherlands
Neuromuscul Disord
(2004) - et al.
Long-term outcome in polymyositis and dermatomyositis
Ann Rheum Dis
(2006) - et al.
Immunosuppressant and immunomodulatory treatment for dermatomyositis and polymyositis
Cochrane Database Syst Rev
(2005) Response of resistant idiopathic thrombocytopenic purpura to pulsed high-dose dexamethasone therapy
N Engl J Med
(1994)- et al.
Corticosteroid use in the treatment of neuromuscular disorders: empirical and evidence-based data
Muscle Nerve
(2004) - et al.
Initial treatment of immune thrombocytopenic purpura with high-dose dexamethasone
N Engl J Med
(2003) - et al.
Pulsed high dose dexamethasone treatment in chronic inflammatory demyelinating polyneuropathy: a pilot study
J Neurol Neurosurg Psychiatry
(1997) - et al.
A prospective, open-label trial assessing dexamethasone pulse therapy in moderate to severe ulcerative colitis
J Clin Gastroenterol
(2002)
Dexamethasone pulse therapy in pemphigus
J Eur Acad Dermatol Venereol
Dexamethasone pharmacokinetics after high-dose oral therapy for pemphigus
Ann Pharmacother
The treatment of idiopathic sudden sensorineural hearing loss using pulse therapy: a prospective, randomized, double-blind clinical trial
Laryngoscope
Oral pulsed high-dose dexamethasone for myositis
J Neurol
Classification criteria for polymyositis and dermatomyositis
J Rheumatol
Interobserver agreement for the assessment of handicap in stroke patients
Stroke
A controlled trial of high-dose intravenous immune globulin infusions as treatment for dermatomyositis
N Engl J Med
Outcome in patients with idiopathic inflammatory myositis: morbidity and mortality
Rheumatology (Oxford)
Cited by (72)
Efficacy and safety of intravenous and subcutaneous immunoglobulin therapy in idiopathic inflammatory myopathy: A systematic review and meta-analysis
2022, Autoimmunity ReviewsCitation Excerpt :However, the included number of patients was small (n = 80) and at least one study had significant missing data. In one study, the onset of improvement was within 3 weeks [1] while this is estimated to be between 4 and 12 weeks with high dosed glucocorticoid therapies [54]. The side effects associated with IVIg are relatively fewer as compared to other conventional therapies like steroids, azathioprine and methotrexate, especially infections.
Dexamethasone Can Be Safely and Effectively Used for Treatment of Masticatory Muscle Myositis in Dogs
2021, Topics in Companion Animal MedicineAntisynthetase syndrome – much more than just a myopathy
2021, Seminars in Arthritis and RheumatismCitation Excerpt :High single-dose alternate-day prednisolone therapy was proposed as an effective and safer than every-day treatment algorithm in polymyositis patients [106]. In the randomised controlled trial oral pulses of dexamethasone in the dose of 40 mg per day administered for 4 days a month showed similar efficacy as standard daily doses, yet ensured reduction of side-effects [107]. In milder cases, corticosteroid monotherapy provides adequate disease control, yet most patients require additional immunosuppressive agents [105].
Polymyositis and dermatomyositis – challenges in diagnosis and management
2019, Journal of Translational AutoimmunityThe clinical management of neuromuscular disorders in intensive care
2019, Neuromuscular DisordersCitation Excerpt :However, treatment should not be delayed while awaiting biopsy, complex histology or antibody tests. Intermittent pulse steroid regimens are increasingly used rather than conventional daily steroids (i.e. repeated 3 day IV methylprednisolone 1000 mg pulse treatments, or oral Dexametasone 40 mg on 4 consecutive days every 4 weeks) [34]. Additional immunomodulation is added according to the clinical response and antibody profile: immune-mediated necrotizing myopathy (IMNM) associated with anti-SRP antibody often presents as a rapidly progressive proximal myopathy, and most cases will need a second line immunosuppressant such as Rituximab [35–39].
Classification and management of adult inflammatory myopathies
2018, The Lancet NeurologyCitation Excerpt :Thus, treatment is largely based on historical clinical practice and case series, and fundamentally guided by the opinion of experts. Glucocorticoids are first-line drugs in the treatment of inflammatory myopathies, but are rarely used as a monotherapy because of their side-effects, such as osteoporosis, hypertension, or weight gain.76 The most commonly prescribed corticosteroid is prednisone, which is typically started at a dose of 0·5–1 mg/kg per day to a maximum dose of 80–100 mg per day.
- 1
Present address: Flevoziekenhuis, Almere, The Netherlands.
- 2
These authors contributed equally to this work.
- #
Members listed at the end of report.